Puma: 3 Key Takeaways for Long-Term Investors

Puma Biotechnology reported Q3 2026 revenue of $55.1 million with three key developments: the company became debt-free after paying off its final loan to Athyrium, generic competition in China reduced royalty revenue by $2.1 million prompting lower full-year guidance, and interim trial data for alisertib supports advancement to phase III breast cancer studies. With $108.5 million in cash and growing U.S. NERLYNX demand, Puma is balancing core product commercialization with clinical expansion while maintaining positive net income.